Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3350759 | 0.76 | KDM4E (0.39) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL15987793 | 0.72 | KDM4E (0.36) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL2057021 | 0.72 | KDM4E (0.36) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL30987223 | 0.72 | MAPT (0.60) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.72 | MAPT (0.60) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL3150476 | 0.67 | MAPT (0.46) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL6964514 | 0.65 | KDM4E (0.52) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL4016240 | 0.65 | NPC1 (0.50) | KDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL4875674 | 0.64 | MAPT (0.39) | KDM4EMAPTALDH1A1HSD17B10EPAS1 | |
| SCHEMBL29801223 | 0.64 | ALDH1A1 (0.42) | KDM4EMAPTALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | KDM4E 3641/4885MAPT 1096/4885ALDH1A1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.